Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma looks to Spain for latest licensing deal

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.
Evgen Pharma looks to Spain for latest licensing deal
Evgen has 60 new chemical entities to add to the pipeline.

Evgen Pharma (LON:EVG) has struck an interesting deal with the Spanish National Research Council and the University of Seville.

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.

Evgen said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds.

As well as the upfront payment, the firm’s new partners will receive cash as the drug or drugs hit certain milestones. They will also receive a royalty on any sales that won’t exceed 1%.

Chief executive Stephen Franklin said: “We are delighted to acquire the exclusive worldwide licensing rights to these novel compounds.

“The University of Seville has conducted an innovative medicinal chemistry programme based on sulforaphane and, like sulforaphane, these novel compounds have a requirement for our patented stabilisation technology.

“These new compounds give us the opportunity to lead the intellectual property space around sulforaphane and to build a drug development pipeline targeting several therapeutic markets within neurology and oncology."

View full EVG profile View Profile

Evgen Pharma Timeline

Article
October 21 2015

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders
test tubes in a laboratory
November 01 2017
If you’re a pharmacist looking to get your hands on an unlicensed drug, there’s a good chance Clinigen can help

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use